University of Arizona School of Medicine, Tucson, Arizona.
St. Joseph Hospital, Orange, California.
J Vasc Interv Radiol. 2022 Feb;33(2):183-188. doi: 10.1016/j.jvir.2021.10.011. Epub 2021 Oct 23.
To investigate the short-term results of single-session treatment of iliocaval and iliofemoral DVT using a single thrombectomy device.
This prospective pilot study analyzed patients with acute iliocaval or iliofemoral DVT treated in a single session using the JETi thrombectomy system. All analyses were performed on an intention-to-treat basis. The cohort consisted of 53 limbs in 47 patients (27 women), with a mean age of 57 years (range, 16-88 years). The primary safety and efficacy endpoints were freedom from major adverse events (MAEs) and reestablishment of unobstructed flow in a single session, respectively.
The mean duration of symptoms was 8.5 days ± SD 9.2, with 10 patients (11 limbs, 21.3%) presenting with a symptom duration of >14 days. Twelve (25.5%) patients had thrombosis of the inferior vena cava and the iliofemoral segments. During the index procedure, unobstructed flow was reestablished in 47 of 53 (88.6%) limbs in 41 of 47 (87.2%) patients (primary endpoint) with no MAEs through 30 days. Overall, unobstructed flow was restored in 50 of 53 (94.3%) limbs and in 44 of 47 (93.6%) patients.
Successful single-session treatment of patients with acute iliocaval and iliofemoral DVT is feasible with a high rate of efficacy and a low rate of adverse events. Such patients may be treated on an outpatient basis.
研究使用单一血栓切除术设备单次治疗髂股静脉和髂静脉血栓形成的短期结果。
这项前瞻性试点研究分析了使用 JETi 血栓切除术系统单次治疗急性髂股静脉或髂静脉血栓形成的患者。所有分析均基于意向治疗进行。该队列由 47 名患者的 53 条肢体组成（27 名女性），平均年龄为 57 岁（范围 16-88 岁）。主要安全性和疗效终点分别为无重大不良事件（MAE）和单次治疗中恢复通畅的无阻塞血流。
症状的平均持续时间为 8.5 天±标准差 9.2，10 名患者（11 条肢体，21.3%）出现症状持续时间>14 天。12 名（25.5%）患者存在下腔静脉和髂股静脉段血栓形成。在指数手术期间，47 名患者中的 41 名（87.2%）的 53 条肢体中的 47 条（87.2%）中的 53 条（主要终点）在 30 天内无 MAE 恢复无阻塞血流。总体而言，53 条肢体中的 50 条（94.3%）和 47 名患者中的 44 条（93.6%）恢复了无阻塞血流。
急性髂股静脉和髂静脉血栓形成患者单次成功治疗是可行的，具有较高的疗效和较低的不良事件发生率。这些患者可能可以在门诊接受治疗。
